Pharmacelsus GmbH

Pharmacelsus is a research-driven CRO (Contract Research Organisation) providing 15 years of high quality preclinical services to life science companies and academic institutions. Pharmacelsus’ service portfolio covers drug discovery and development process, in vitro, in vivo, ex vivo and bioanalytical studies. The company has been GLP-certified since 2008.

Our portfolio encompasses:   

  • In vitro ADME studies (Absorption, Distribution, Metabolism, Elimination) e.g. stability, membrane permeability and transport, protein binding, drug-drug interactions, metabolism    
  • In vivo pharmacokinetic studies in rodents (bioavailability, identification of metabolites)      
    Single or cassette dosing, numerous application routes    
  • In vitro toxicology (cytotoxicity, hepatotoxicity, immuntoxicity, 2D cell culture and 3D organoid structures
  • LC-MS/MS bioanalytics (GCLP, GLP and non-GLP) Quantification of small molecules and phytopharmaceuticals in plasma, tissue, urine and faeces       
    GLP method development       
    GLP method validation       
    GLP bioanalytics for multi-site in vivo toxicology and clinical trials
    Identification of metabolites     
  • In vitro and in vivo pharmacology (steroid-endocrinology, liver fibrosis, histamine release, diabetes)
  • Endocrine disruptors (REACH)

For several years, Pharmacelsus successfully participates in funded research projects covering different research programs (EU FP6 and FP7, Horizon 2020, BMWi, BMBF, Eurostars, etc.).
Within ZIM Cooperation network Nanopharm, we offer our entire portfolio, particularly in vivo studies for the determination of bioavailability and/ or bioequivalence, in vitro nanotoxicological studies and quantification of small molecules and phytopharmaceuticals via LC-MS.